The corresponding statement was made at a meeting of the heads of services of the member states of the Shanghai Cooperation Organization (SCO), responsible for ensuring sanitary and epidemiological well-being.
“In June, we will complete preclinical studies of the efficacy and safety of the vaccine in the minimum amount necessary for the transition to the first and second phases of clinical trials for a total of 300 volunteers, and we expect the launch of studies on volunteers from July 15,” TASS quoted Maksyutova.
According to him, during the study, three drugs were selected for further clinical trials, based on which recommendations will be developed on the use of the vaccine by certain groups of the population.
The "Vector" is awaiting registration of the first vaccine preparation in the fall.
Earlier, the Russian Ministry of Defense and the Gamalei Research Center for Epidemiology and Microbiology began testing human coronavirus vaccines.
Virologist Fedor Lisitsyn, in an interview with the Zvezda television channel, spoke about the type of vaccine against coronavirus being developed in Russia.